Skip to content
type1.science

CRISPR Therapeutics hypoimmune islets (CTX211 → CTX213)

CRISPR Therapeutics (originated via ViaCyte; licensed to Vertex Pharmaceuticals 2023–2024)

The trial stopped; the programme did not — but it is back to preclinical.

Allogeneic, stem-cell-derived islet cells gene-edited with CRISPR-Cas9 to be "hypoimmune" — cloaked well enough to survive without lifelong immunosuppression. The first-in-human product, VCTX211 (later CTX211), put the cloaked cells inside a retrievable perforated pouch; its Phase 1 was terminated in 2025 after 5 people, and no results were ever posted. The trial stopped, but the programme did not: CRISPR Therapeutics says CTX211 produced detectable C-peptide at 12 months and has carried that forward into a device-free successor, CTX213. Read the two halves separately. The human evidence is a single unquantified company sentence; the live candidate, CTX213, is preclinical — no IND, no trial, no human data as of July 2026.

Years awayEarly evidencestem-cellisletgene-editinghypoimmuneimmune-evasioncrisprencapsulationallogeneiccombinationcell-therapy

The scorecard

Efficacy38

CRISPR Therapeutics reported that CTX211 (formerly VCTX211) produced detectable C-peptide 12 months after implantation — the first sign the cloaked cells made insulin in people. No numbers, no insulin-independence data, and no peer-reviewed or registry results have been posted, so the size of the effect is unknown.[1]

Durability30

Cloaked cells must survive both rejection and recurrent autoimmunity long-term; durability in people is unproven and the small trial reported no graft-survival readout.

Safety50

Retrievable device aids removal and gene editing raises off-target/growth concerns; no VCTX211 safety signal was reported, and the 2024 patient deaths were in a separate Vertex program (VX-880), not this one.

Eligibility breadth55

Designed to need no immunosuppression — and the Phase 1 was genuinely run that way, excluding anyone on chronic immunosuppressive therapy — and allogeneic (off-the-shelf), which could open cell therapy to the broad T1D population if it works. The trial enrolled adults 18-65 with T1D for 5+ years. Scored on the design's reach, not on a proven product: nothing has shown it works.

Immunosuppression-free60

Drug-free in people, not just on paper: the Phase 1 protocol excluded chronic immunosuppression outright, so all 5 recipients carried the cloaked cells with no anti-rejection drugs, and the company says C-peptide was still detectable at 12 months. That is real human drug-free exposure — which is why this scores well above lifelong-immunosuppression cell therapies. But it sits below Sana (75), whose drug-free graft survival is peer-reviewed, because here the entire human record is one unquantified sentence in a press release. The readouts that would actually show the cloak held — graft immune infiltration, viable graft cells, new alloreactive and autoreactive antibodies — were all pre-specified secondary outcomes and none were ever posted. A transplant faces both rejection and the returning autoimmunity; the edits target both, and nobody has published whether either was held off. The live candidate, CTX213, has no human data at all.[4]

Maturity30

The programme is alive but has gone backwards in stage, and the score follows the stage, not the intent. The 5-patient Phase 1 (NCT05565248) is still TERMINATED with no results posted, and the successor CTX213 is preclinical: CRISPR's own pipeline page lists it below the clinical column, no IND or CTA has been announced, and a ClinicalTrials.gov search for CTX213 returned no studies on 2026-07-15. "Progressing toward the clinic" is a company timeline, not a milestone.[5]

Immunosuppression-free is scored here, as it is for cell replacement and encapsulation — freeing a therapy from lifelong anti-rejection drugs is the central barrier this whole pillar is trying to clear, so an approach that achieves it must be able to earn credit for it. It is scored on evidence, not intent: a platform designed to avoid immunosuppression but never yet tested at a therapeutic dose scores on what it has shown. Approaches that transplant nothing (in-vivo gene therapy, reprogramming) need no anti-rejection drugs by construction, but they still face the original autoimmune attack — that unresolved risk belongs in this score, not hidden by it.

The full picture

Read this record as a programme, not a product. The trial you may have heard was cancelled really was cancelled — but CRISPR Therapeutics did not quit type 1 diabetes. The first-in-human product, VCTX211 (later renamed CTX211), was terminated in 2025 after five people. The company then said those cells were still making detectable C-peptide at 12 months, and carried the technology into a next-generation candidate, CTX213. So: the trial stopped, the programme continued — and the programme is now earlier than it was, because CTX213 has never been in a human.123

VCTX211 is a "cloak, don't cage" attempt at a drug-free cure for type 1 diabetes. It combines two technologies: lab-grown insulin-producing islet cells (made from a stem-cell line, called PEC211 pancreatic endoderm cells) and CRISPR-Cas9 gene editing that rewrites those cells to be "hypoimmune" — engineered so the immune system is far less able to see and destroy them.45 The goal is a transplant that survives without the lifelong immunosuppressant drugs that today's islet transplants require.6

How the cloaking works. The cells are edited to remove the surface flags (HLA class I, via knockout of the B2M gene) that the immune system reads as "foreign," and to add molecules that actively calm immune cells — including PD-L1 and HLA-E, plus survival-boosting edits (TNFAIP3, MANF) and a metabolic tweak (TXNIP knockout).7 This builds on a well-published "hypoimmune" concept: removing HLA and over-expressing a "don't-eat-me" signal lets edited cells evade rejection in animal models and, in related cell-therapy programs, in people.89 As a belt-and-braces measure, VCTX211 is also loaded into a small, removable, perforated pouch implanted under the skin, so the graft can be retrieved if needed.45

The lineage. VCTX211 is the second generation. Its predecessor, VCTX210 (B2M knockout plus PD-L1), was a proof-of-concept; VCTX211 added "novel edits to promote cell survival" and was cleared by Health Canada in late 2022.710

Clinical evidence. A first-in-human, open-label Phase 1 study (NCT05565248) ran at two Canadian sites, enrolling adults aged 18-65 who had lived with T1D for at least five years.6 Crucially, chronic immunosuppression was an exclusion criterion — confirming the immunosuppression-free design.6 The trial was meant to measure safety plus C-peptide (a marker of the body's own insulin), insulin use, hypoglycemia, HbA1c, time-in-range, graft immune infiltration, and new anti-graft antibodies.6 The study was terminated (primary completion August 2025) with only 5 participants, the sponsor stating patients would be "followed up in the VCTX-201 study."6

No results were ever posted to the trial registry — as of July 2026 the record still shows no data.6 What we have instead is a statement from the company: in January 2026 CRISPR Therapeutics said the clinical data from CTX211 (the renamed VCTX211) were "promising, demonstrating detectable C-peptide levels 12 months after implantation."1 Read that carefully. It is genuinely encouraging — it is the first hint that cloaked, gene-edited cells survived and made insulin inside a person a full year after implant, without immunosuppressants. But it is a company press release, not published data: there are no numbers, no comparison group, no peer review, and no word on whether anyone needed less injected insulin. "Detectable C-peptide" can mean a trace far too small to matter clinically. Until real figures appear, how well this worked remains unknown.

Corporate twists matter here. The program came from ViaCyte (acquired by Vertex in 2022) and CRISPR Therapeutics; in March 2023 Vertex paid $100 million up front (up to $230 million in milestones) for rights to the hypoimmune technology.1112 In January 2024 Vertex ended the diabetes collaboration, leaving CRISPR Therapeutics to develop the asset alone, now branded CTX211.13 (Note: two 2024 patient deaths that made headlines were in Vertex's separate VX-880/zimislecel trial, not VCTX211.)13

Safety and durability. The retrievable device is a deliberate safety feature, and editing raises standard concerns about off-target effects and uncontrolled growth — but no VCTX211-specific safety problems were reported.48 Durability against both rejection and the original autoimmunity is the central open question, and the trial never produced a formal graft-survival readout.6

What's coming — the programme, not the product. VCTX211 is wound down as a standalone product; its real legacy is as a stepping stone. CRISPR Therapeutics says the CTX211 data "informed the Company's approach to hypoimmune cell engineering, supporting a transition to a next-generation candidate, CTX213."1 CTX213 is a notable shift: it is deviceless — "unencapsulated precursor islet cells derived from edited induced pluripotent stem cells (iPSCs)," given by direct administration rather than sealed in a pouch.2 In other words, the cloak without the cage. CTX213 is the only type 1 diabetes candidate on the company's pipeline today; CTX211 has been removed from it.3

But preclinical is preclinical. The company reports "compelling preclinical efficacy" and says CTX213 is "progressing toward the clinic."12 Both of those are statements about animals and intentions. As of 15 July 2026, CTX213 has no IND, no clinical trial application, no registered trial and no human data: the pipeline chart does not mark it as clinical-stage, and a ClinicalTrials.gov query for CTX213 returns zero studies — the registry's only CRISPR Therapeutics diabetes entries are still VCTX210A (completed) and VCTX211 (terminated).314 So the honest summary is that this programme has a live idea, a dead trial, and a candidate that has not yet been given to a person. It went back a step to try to go forward.

The bigger picture: the hypoimmune "cloak" strategy is being pursued across the field (e.g., Sana Biotechnology's B2M/CIITA-knockout, CD47-overexpressing cells), so even though this specific product has been shelved, the approach it pioneered is very much alive.79

References

References

  1. CRISPR Therapeutics. CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones — "Clinical data generated from CTX211 were promising, demonstrating detectable C-peptide levels 12 months after implantation… These data have informed the Company's approach to hypoimmune cell engineering, supporting a transition to a next-generation candidate, CTX213." Company press release; figures not given and not peer-reviewed. CRISPR Therapeutics / GlobeNewswire (January 12, 2026). https://www.globenewswire.com/news-release/2026/01/12/3216929/0/en/crispr-therapeutics-highlights-strategic-priorities-and-anticipated-2026-milestones.html ↩ ↩2 ↩3 ↩4

  2. CRISPR Therapeutics. CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results — CTX213 described as "a deviceless beta cell replacement candidate for Type 1 diabetes, consisting of unencapsulated precursor islet cells derived from edited induced pluripotent stem cells (iPSCs)," which "has demonstrated compelling preclinical efficacy through direct administration and is progressing toward the clinic." CRISPR Therapeutics / GlobeNewswire (May 4, 2026). https://www.globenewswire.com/news-release/2026/05/04/3287176/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-First-Quarter-2026-Financial-Results.html ↩ ↩2 ↩3

  3. CRISPR Therapeutics. Pipeline — CTX213 listed under Regenerative Medicine as an "unencapsulated investigational allogeneic, gene-edited, immune-evasive, stem cell-derived beta-cell replacement therapy" for type 1 diabetes (wholly owned); not marked clinical-stage, and CTX211 no longer appears. CRISPR Therapeutics (accessed 15 July 2026). https://crisprtx.com/pipeline ↩ ↩2 ↩3

  4. ClinicalTrials.gov. An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (NCT05565248). U.S. National Library of Medicine (2023–2026). https://clinicaltrials.gov/study/NCT05565248 ↩ ↩2 ↩3

  5. CRISPR Medicine News. Clinical trial: Type 1 Diabetes (NCT05565248) — VCTX211 allogeneic gene-edited PEC211 cells plus durable, removable perforated device. CRISPR Medicine (2023). https://crisprmedicinenews.com/clinical-trial/type-1-diabetes-t1d-nct05565248/ ↩ ↩2

  6. ClinicalTrials.gov. NCT05565248 record — status TERMINATED, 5 participants, primary completion 2025-08-08, reason "Patients to be followed up in the VCTX-201 study"; eligibility (T1D ≥5 years, ages 18-65, chronic immunosuppression excluded) and outcome measures (C-peptide, insulin use, HbA1c, time-in-range, anti-graft antibodies). U.S. National Library of Medicine (accessed 2026). https://clinicaltrials.gov/study/NCT05565248 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  7. Technology Networks. Gene-Edited Stem Cell-Derived Therapies — A Functional Cure for T1D? (VCTX210: B2M knockout + PD-L1; VCTX211: B2M and TXNIP knockouts plus PD-L1, HLA-E, TNFAIP3 and MANF insertions). Technology Networks (2024). https://www.technologynetworks.com/biopharma/blog/gene-edited-stem-cell-derived-therapies-a-functional-cure-for-t1d-357837 ↩ ↩2 ↩3

  8. Hu X, Manner K, DeJesus R, et al. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice (B2M/CIITA/TRAC knockout + CD47 over-expression; CD47-targeting safety strategy). Nature Communications (2023). https://doi.org/10.1038/s41467-023-37785-2 ↩ ↩2

  9. Hu X, Beauchesne P, Wang C, et al. Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease (clinical evidence that HLA-depleted, CD47-overexpressing cells avoid alloimmune attack). Cell Stem Cell (2025). https://doi.org/10.1016/j.stem.2025.07.009 ↩ ↩2

  10. CRISPR Therapeutics. CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results (VCTX211 includes novel edits to promote cell survival; Health Canada cleared the clinical trial application in late 2022). CRISPR Therapeutics / GlobeNewswire (November 1, 2022). https://www.globenewswire.com/en/news-release/2022/11/01/2545957/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2022-Financial-Results.html ↩

  11. CRISPR Therapeutics. CRISPR Therapeutics and Vertex Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes (March 27, 2023; $100M upfront, up to $230M milestones plus royalties; VCTX211 Phase 1/2 ongoing). CRISPR Therapeutics (2023). https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-and-vertex-announce-licensing-agreement-to-accelerate-development-of-vertexs-hypoimmune-cell-therapies-for-the-treatment-of-type-1-diabetes ↩

  12. Pharmaceutical Technology. Vertex signs licence deal with CRISPR for diabetes therapies ($100m upfront, up to $230m in R&D milestones; VCTX211 Phase I/II ongoing; hypoimmune islet cells for T1D). Pharmaceutical Technology (2023). https://www.pharmaceutical-technology.com/news/vertex-crispr-diabetes-therapies/ ↩

  13. Pharma Manufacturing. Vertex axes diabetes cell therapy deal with CRISPR (collaboration ended early 2024; CRISPR Therapeutics takes sole responsibility for CTX211 / formerly VCTX211, an immunosuppression-free beta-cell replacement). Pharma Manufacturing (2024). https://www.pharmamanufacturing.com/industry-news/news/33017292/vertex-axes-diabetes-cell-therapy-deal-with-crispr ↩ ↩2

  14. ClinicalTrials.gov. Registry query for "CTX213" returns zero studies; a CRISPR Therapeutics + diabetes sponsor search returns only NCT05210530 (VCTX210A, completed) and NCT05565248 (VCTX211, terminated). U.S. National Library of Medicine (run 15 July 2026). https://clinicaltrials.gov/api/v2/studies?query.term=CTX213&format=json ↩

Coming soon

ETA · No human trial is running. The CTX211 Phase 1 (NCT05565248) was terminated in 2025; the programme continues as CTX213, a device-free successor that is preclinical — no IND, no CTA, no registered trial as of July 2026. Even on the company's own "progressing toward the clinic" language, first-in-human dosing has not been scheduled publicly

  • →An IND or CTA for CTX213 — the milestone that would put this programme back in the clinic · not announced
  • →Any actual numbers behind the "detectable C-peptide at 12 months" claim (registry results or a publication from the terminated CTX211 trial) · not announced
  • →CTX211 trial participants followed up in the VCTX-201 study

Sources

  1. [1]CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones · manufacturer · 2026-01-12 — Verbatim (verified 2026-07-15) "Clinical data generated from CTX211 were promising, demonstrating detectable C-peptide levels 12 months after implantation." / "These data have informed the Company's approach to hypoimmune cell engineering, supporting a transition to a next-generation candidate, CTX213." / "CTX213 has demonstrated compelling preclinical efficacy and is progressing towards the clinic." Company claim — no numbers, no peer review.
  2. [2]CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results · manufacturer · 2026-05-04 — Verbatim (verified 2026-07-15) CTX213 is "a deviceless beta cell replacement candidate for Type 1 diabetes, consisting of unencapsulated precursor islet cells derived from edited induced pluripotent stem cells (iPSCs)" and "has demonstrated compelling preclinical efficacy through direct administration and is progressing toward the clinic." Preclinical, by the company's own word.
  3. [3]CRISPR Therapeutics pipeline — CTX213 (Regenerative Medicine) · manufacturer — Accessed 2026-07-15. CTX213 is listed as an "unencapsulated investigational allogeneic, gene-edited, immune-evasive, stem cell-derived beta-cell replacement therapy" for type 1 diabetes, wholly owned, and is not marked as clinical-stage. CTX211 no longer appears on the pipeline.
  4. [4]NCT05565248 — VCTX211 first-in-human study: TERMINATED, 5 participants, no results posted (accessed 2026-07-15) · registry — Re-checked 2026-07-15 status still TERMINATED, enrolment 5, primary completion 2025-08-08, no results posted. Chronic immunosuppression was an exclusion criterion ("Immunosuppressant therapy in the previous 30 days and/or requirements for chronic immunosuppressive therapy during the study"), which is what makes the drug-free claim real. Pre-specified secondary outcomes included graft immune infiltration, viable graft cells, and new alloreactive/autoreactive antibodies — none reported.
  5. [5]ClinicalTrials.gov query for CTX213 — no studies returned · registry — Run 2026-07-15 the registry returns zero studies for CTX213. A sponsor search (CRISPR Therapeutics + diabetes) returns only NCT05210530 (VCTX210A, completed) and NCT05565248 (VCTX211, terminated). CTX213 has no registered human trial.